A Efficacy and Safety Study of Adefovir Dipivoxil to Treat Chinese Patients With HBeAg+ve Chronic Hepatitis B

GlaxoSmithKline (GSK) logo

GlaxoSmithKline (GSK)

Status and phase

Completed
Phase 3

Conditions

Chronic Hepatitis B

Treatments

Drug: PAAA
Drug: AAAA
Drug: AAPA

Study type

Interventional

Funder types

Industry

Identifiers

NCT00857675
ADF30001

Details and patient eligibility

About

The purpose of this study is to determine whether Adefovir Dipivoxil is effective and safe in treatment of Chinese Patients with HBeAg positive Chronic Hepatitis B for 5 years.

Enrollment

480 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Aged 18-65 years
  • Presence of HBsAg and HBeAg at the time of screening and for at least 6 months prior to screening.
  • Positive HBV DNA plasma assay with screening value equal or more than 10 (6) copies/mL (Roche COBAS AMPLICORTM HBV MONITOR Test, LLOD less than 300 copies/mL) at the time of screening (within 4 weeks of randomisation).
  • Evidence of elevated serum ALT levels defined as serum ALT level greater than or equal to 2.0 times (inclusive) the upper limit of the normal range (ULN) in the previous 6 months, and serum ALT levels greater than 1.0 times the ULN at the time of screening.

Exclusion criteria

  • Evidence of hepatocellular carcinoma;
  • Clinical signs of liver decompensation;
  • Serum creatinine more than 1.5 mg/dL;
  • ALT more than 10 x ULN; seropositivity for hepatitis C or D virus or HIV;
  • Lamivudine therapy within 3 months prior to screening;
  • ADV therapy or any other anti-HBV therapy within the previous 6 months;
  • Use of systemic antiviral agents, immunomodulators, immunosuppressive therapy, Chinese Traditional Medicines or agents known to lower ALT levels during the study.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

480 participants in 2 patient groups, including a placebo group

Adefovir Dipivoxil
Experimental group
Description:
ADV 10mg tablets once daily
Treatment:
Drug: AAPA
Drug: AAAA
Drug: PAAA
Adefovir Dipivoxil matched placebo
Placebo Comparator group
Description:
Adefovir Dipivoxil matched placebo one tablet once daily
Treatment:
Drug: AAPA
Drug: PAAA

Trial contacts and locations

10

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems